Skip to main content
SpringerLink
Log in

Targeting mutant kinases in Gastrointestinal Stromal Tumors: A paradigm for molecular therapy of other sarcomas

  • Chapter
Targeting Treatment of Soft Tissue Sarcomas

Part of the book series: Cancer Treatment and Research ((CTAR,volume 120))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Besmer, P., Murphy, J. E., George, P. C., Qiu, F., Bergold, P. J., Lederman, L., Snyder, H. W., Jr., Brodeur, D., Zuckerman, E. E., and Hardy, W. D. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature., 320: 415–419, 1986.

    Article  CAS  PubMed  Google Scholar 

  2. Yarden, Y., Kuang, W.-J., Yang-Feng, T., Coussens, L., Munemitsu, S., Dull, T. J., Chen, E., Schlessinger, J., Francke, U., and Ullrich, A. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J., 11: 3341–3351, 1987.

    Google Scholar 

  3. Rousset, D., Agnes, F., Lachaume, P., Andre, C., and Galibert, F. Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulinlike domains. Journal of Molecular Evolution, 41: 421–429, 1995.

    Article  CAS  PubMed  Google Scholar 

  4. Small, D., Levenstein, M., Kim, E., Carow, C., Amin, S., Rockwell, P., Witte, L., Burrow, C., Ratajczak, M. Z., Gewirtz, A. M., and et al STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc.Natl.Acad.Sci.U.S.A., 91: 459–463, 1994.

    CAS  PubMed  Google Scholar 

  5. Ishikawa, K., Komuro, T., Hirota, S., and Kitamura, Y. Ultrastructural identification of the c-kit-expressing interstitial cells in the rat stomach: a comparison of control and Ws/Ws mutant rats. Cell & Tissue Research, 289: 137–143, 1997.

    CAS  Google Scholar 

  6. Natali, P. G., Nicotra, M. R., Sures, I., Santoro, E., Bigotti, A., and Ullrich, A. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res., 52: 6139–6143, 1992.

    CAS  PubMed  Google Scholar 

  7. Nocka, K., Majumder, S., Chabot, B., Ray, P., Cervone, M., Bernstein, A., Besmer, and P. Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice-evidence for an impaired c-kit kinase in mutant mice. Genes Dev., 3: 816–826, 1989.

    CAS  PubMed  Google Scholar 

  8. Russell, E. S. Hereditary anemias of the mouse: A review for geneticists. Adv.Genet., 20: 357–359, 1979.

    CAS  PubMed  Google Scholar 

  9. Turner, A. M., Zsebo, K. M., Martin, F., Jacobsen, F. W., Bennett, L. G., and Broudy, V. C. Nonhematopoietic tumor cell lines express stem cell factor and display ckit receptors. Blood, 80: 374–381, 1992.

    CAS  PubMed  Google Scholar 

  10. Blume-Jensen, P., Claesson-Welsh, L., Siegbahn, A., Zsebo, K. M., Westermark, B., and Heldin, C. H. Activation of the human c-kit product by ligandinduced dimerization mediates circular actin reorganization and chemotaxis. EMBO J., 10: 4121–4128, 1991.

    CAS  PubMed  Google Scholar 

  11. Huang, E., Nocka, K., Beier, D. R., Chu, T. Y., Buck, J., Lahm, H. W., Wellner, D., Leder, P., and Besmer, P. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell, 63: 225–233, 1990.

    Article  CAS  PubMed  Google Scholar 

  12. Blume-Jensen, P. and Hunter, T, Oncogenic kinase signalling. Nature., 411: 355–365, 2001.

    Article  CAS  PubMed  Google Scholar 

  13. Irusta, P. M. and DiMaio, D. A single amino acid substitution in a WW-like domain of diverse members of the PDGF receptor subfamily of tyrosine kinases causes constitutive receptor activation. EMBO J., 17: 6912–6923, 1998.

    Article  CAS  PubMed  Google Scholar 

  14. Kitayama, H., Kanakura, Y., Furitsu, T., Tsujimura, T., Oritani, K., Ikeda, H., Sugahara, H., Mitsui, H., Kanayama, Y., Kitamura, Y., and et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood, 85: 790–798, 1995.

    CAS  PubMed  Google Scholar 

  15. Ma, Y., Cunningham, M. E., Wang, X., Ghosh, I., Regan, L., and Longley, B. J. Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region. J.Biol.Chem., 274: 13399–13402, 1999.

    CAS  PubMed  Google Scholar 

  16. Chan, P. M., Ilangumaran, S., La Rose, J., Chakrabartty, A., and Rottapel, R. Autoinhibition of the Kit Receptor Tyrosine Kinase by the Cytosolic Juxtamembrane Region. Mol.Cell Biol., 23: 3067–3078, 2003.

    Article  CAS  PubMed  Google Scholar 

  17. Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., Muhammad Tunio, G., Matsuzawa, Y., Kanakura, Y., Shinomura, Y., and Kitamura, Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 279: 577–580, 1998.

    Article  CAS  PubMed  Google Scholar 

  18. Rubin, B. P., Singer, S., Tsao, C., Duensing, A., Lux, M. L., Ruiz, R., Hibbard, M. K., Chen, C. J., Xiao, S., Tuveson, D. A., Demetri, G. D., Fletcher, C. D. M., and Fletcher, J. A. KIT Activation Is a Ubiquitous Feature of Gastrointestinal Stromal Tumors. Cancer Res, 61: 8118–8121, 2001.

    CAS  PubMed  Google Scholar 

  19. Ernst, S. I., Hubbs, A. E., Przygodzki, R. M., Emory, T. S., Sobin, L. H., and O’Leary, T. J. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Laboratory Investigation, 78: 1633–1636, 1998.

    CAS  PubMed  Google Scholar 

  20. Lasota, J., Jasinski, M., Sarlomo-Rikala, M., and Miettinen, M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am.J.Pathol., 154: 53–60, 1999.

    CAS  PubMed  Google Scholar 

  21. Li, S. Q., O’Leary, T. J., Sobin, L. H., Erozan, Y. S., Rosenthal, D. L., and Przygodzki, R. M. Analysis of KIT mutation and protein expression in fine needle aspirates of gastrointestinal stromal/smooth muscle tumors. Acta Cytologica, 44: 981–986, 2000.

    CAS  PubMed  Google Scholar 

  22. Moskaluk, C. A., Tian, Q., Marshall, C. R., Rumpel, C. A., Franquemont, D. W., Frierson, and Jr, H. F. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene, 18: 1897–1902, 1999.

    Article  CAS  PubMed  Google Scholar 

  23. Singer, S., Rubin, B. P., Lux, M. L., Chen, C. J., Demetri, G. D., Fletcher, C. D., and Fletcher, J. A. Prognostic Value of KIT Mutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors. J Clin.Oncol.,20: 3898–3905, 2002.

    Article  CAS  PubMed  Google Scholar 

  24. Taniguchi, M., Nishida, T., Hirota, S., Isozaki, K., Ito, T., Nomura, T., Matsuda, H., and Kitamura, Y. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.Cancer Res, 59: 4297–4300, 1999.

    CAS  PubMed  Google Scholar 

  25. Emile, J. F., Lemoine, A., Bienfait, N., Terrier, P., Azoulay, D., and Debuire, B. Length analysis of polymerase chain reaction products: a sensitive and reliable technique for the detection of mutations in KIT exon 11 in gastrointestinal stromal tumors. Diagn.Mol.Pathol., 11: 107–112, 2002.

    Article  PubMed  Google Scholar 

  26. Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C. J., Van den Abbeele, A. D., Druker, B. J., Kiese, B., Eisenberg, B., Roberts, P. J., Singer, S., Fletcher, C. D. M., Silberman, S., Dimitrijevic, S., and Fletcher, J. A. Kinase mutations and imatinib mesylate response in patients with metastatic gastrointestinal stromal tumor. Journal of Clinical Oncology (in press), 2003.

    Google Scholar 

  27. Corless, C. L., McGreevey, L., Haley, A., Town, A., and Heinrich, M. C. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am.J.Pathol., 160: 1567–1572, 2002.

    CAS  PubMed  Google Scholar 

  28. Lux, M. L., Rubin, B. P., Biase, T. L., Chen, C. J., Maclure, T., Demetri, G., Xiao, S., Singer, S., Fletcher, C. D. M., and Fletcher, J. A. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am.J.Pathol., 156: 791–795, 2000.

    CAS  PubMed  Google Scholar 

  29. Hirota, S., Nishida, T., Isozaki, K., Taniguchi, M., Nakamura, J., Okazaki, T., and Kitamura, Y. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. Journal of Pathology, 193: 505–510, 2001.

    Article  CAS  PubMed  Google Scholar 

  30. Lasota, J., Wozniak, A., Sarlomo-Rikala, M., Rys, J., Kordek, R., Nassar, A., Sobin, L. H., and Miettinen, M. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors: A study of 200 cases. Am.J Pathol., 157: 1091–1095, 2000.

    CAS  PubMed  Google Scholar 

  31. Sakurai, S., Oguni, S., Hironaka, M., Fukayama, M., Morinaga, S., and Saito, K. Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese. Jpn.J.Cancer Res., 92: 494–498, 2001.

    CAS  PubMed  Google Scholar 

  32. Miettinen, M., Kopczynski, J., Makhlouf, H. R., Sarlomo-Rikala, M., Gyorffy, H., Burke, A., Sobin, L. H., and Lasota, J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am.J Surg.Pathol., 27: 625–641, 2003.

    PubMed  Google Scholar 

  33. Kinoshita, K., Isozaki, K., Hirota, S., Nishida, T., Chen, H., Nakahara, M., Nagasawa, Y., Ohashi, A., Shinomura, Y., Kitamura, Y., and Matsuzawa, Y. c-kit Gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol.Hepatol., 18: 147–151, 2003.

    CAS  PubMed  Google Scholar 

  34. Heinrich, M. C., Corless, C. L., Blanke, C. D., Demetri, G., Joensuu, H., von Mehren, M., McGreevey, L., Wait, C.L., Griffith, D., Chen, C. J., Haley, A., Kiese, B., Druker, B., Roberts, P. J., Eisenberg, B. L., Singer, S., Silberman, S., Dimitrijevic, S., Fletcher, C. D., and Fletcher, J. A. KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Proc Am Soc Clin Oncol 21, 2a. 2002.

    Google Scholar 

  35. Chen, H., Isozaki, K., Kinoshita, K., Ohashi, A., Shinomura, Y., Matsuzawa, Y., Kitamura, Y., and Hirota, S. Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors. Int.J.Cancer,105: 130–135, 2003.

    Article  CAS  PubMed  Google Scholar 

  36. Hirota, S., Nishida, T., Isozaki, K., Taniguchi, M., Nishikawa, K., Ohashi, A., Takabayashi, A., Obayashi, T., Okuno, T., Kinoshita, K., Chen, H., Shinomura, Y., and Kitamura, Y. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology,122: 1493–1499, 2002.

    Article  PubMed  Google Scholar 

  37. Buttner, C., Henz, B. M., Welker, P., Sepp, N. T., and Grabbe, J. Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J.Invest.Dermatol., 111: 1227–1231, 1998.

    Article  CAS  PubMed  Google Scholar 

  38. Gari, M., Goodeve, A., Wilson, G., Winship, P., Langabeer, S., Linch, D., Vandenberghe, E., Peake, I., and Reilly, J. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br.J.Haematol., 105: 894–900, 1999.

    Article  CAS  PubMed  Google Scholar 

  39. Hongyo, T., Li, T., Syaifudin, M., Baskar, R., Ikeda, H., Kanakura, Y., Aozasa, and Nomura, T. Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res, 60: 2345–2347, 2000.

    CAS  PubMed  Google Scholar 

  40. Longley, B. J., Tyrrell, L., Lu, S. Z., Ma, Y. S., Langley, K., Ding, T. G., Duffy, T., Jacobs, P., Tang, L. H., and Modlin, I. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nature Genetics,12: 312–314, 1996.

    Article  CAS  PubMed  Google Scholar 

  41. Nagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S., Suzuki, Y., and Metcalfe, D. D. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc.Natl.Acad.Sci.U.S.A., 92: 10560–10564, 1995.

    CAS  PubMed  Google Scholar 

  42. Tian, Q., Frierson, H. F. J., Krystal, G. W., and Moskaluk, C. A. Activating c-skit gene mutations in human germ cell tumors. Am.J.Pathol., 154: 1643–16470, 1999.

    CAS  PubMed  Google Scholar 

  43. Wardelmann, E., Neidt, I., Bierhoff, E., Speidel, N., Manegold, C., Fischer, H. P., Pfeifer, U., and Pietsch, T. c-kit mutations in gastrointestinal stromal tumors occur preferentially in the spindle rather than in the epithelioid cell variant. Mod.Pathol., 15: 125–136, 2002.

    Article  PubMed  Google Scholar 

  44. Heinrich, M. C., Rubin, B. P., Longley, B. J., and Fletcher, J. A. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol, 33: 486–495, 2002.

    Article  Google Scholar 

  45. Corless, C. L., Fletcher, J. A., and Heinrich, M. C. Biology of gastrointestinal stromal tumors. Journal of Clinical Oncology (submitted), 2003.

    Google Scholar 

  46. Beghini, A., Tibiletti, M. G., Roversi, G., Chiaravalli, A. M., Serio, G., Capella, C., and Larizza, L. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer, 92: 657–662, 2001.

    Article  CAS  PubMed  Google Scholar 

  47. Maeyama, H., Hidaka, E., Ota, H., Minami, S., Kajiyama, M., Kuraishi, A., Mori, H., Matsuda, Y., Wada, S., Sodeyama, H., Nakata, S., Kawamura, N., Hata, S., Watanabe, M., Iijima, Y., and Katsuyama, T. Familial Gastrointestinal Stromal Tumor With Hyperpigmentation: Association With a Germline Mutation of the c-kit Gene. Gastroenterology, 120: 210–215, 2001.

    CAS  PubMed  Google Scholar 

  48. O’Brien, P., Kapusta, L., Dardick, I., Axler, J., and Gnidec, A. Multiple familial gastrointestinal autonomic nerve tumors and small intestinal neuronal dysplasia. Am.J.Surg.Pathol., 23: 198–204, 1999.

    Google Scholar 

  49. Hirota, S., Okazaki, T., Kitamura, Y., O’Brien, P., Kapusta, L., and Dardick, I. Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene [letter]. American Journal of Surgical Pathology, 24: 326–327, 2000.

    Article  CAS  PubMed  Google Scholar 

  50. Nishida, T., Hirota, S., Taniguchi, M., Hashimoto, K., Isozaki, K., Nakamura, H., Kanakura, Y., Tanaka, T., Takabayashi, A., Matsuda, H., and Kitamura, Y. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nature Genetics, 19: 323–324, 1998.

    Article  CAS  PubMed  Google Scholar 

  51. Isozaki, K., Terris, B., Belghiti, J., Schiffman, S., Hirota, S., and Vanderwinden, J.-M, Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am.J Pathol., 157: 1581–1585, 2000.

    CAS  PubMed  Google Scholar 

  52. Chen, H., Hirota, S., Isozaki, K., Sun, H., Ohashi, A., Kinoshita, K., O’Brien, P., Kapusta, L., Dardick, I., Obayashi, T., Okazaki, T., Shinomura, Y., Matsuzawa, Y., and Kitamura, Y. Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumours. Gut, 51: 793–796, 2002.

    Article  CAS  PubMed  Google Scholar 

  53. Sommer, G., Agosti, V., Ehlers, I., Rossi, F., Corbacioglu, S., Farkas, J., Moore, M., Manova, K., Antonescu, C. R., and Besmer, P. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl.Acad.Sci.U.S.A, 100: 6706–6711, 2003.

    Article  CAS  PubMed  Google Scholar 

  54. Frost, D., Lasota, J., and Miettinen, M. Gastrointestinal stromal tumors and leiomyomas in the dog: a histopathologic, immunohistochemical, and molecular genetic study of 50 cases. Vet.Pathol, 40: 42–54, 2003.

    Article  CAS  PubMed  Google Scholar 

  55. Heinrich, M. C., Rubin, B. P., Longley, B. J., and Fletcher, J. A. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum.Pathol, 33: 484–495, 2002.

    Article  CAS  PubMed  Google Scholar 

  56. Faderl, S., Talpaz, M., Estrov, Z., O’Brien, S., Kurzrock, R., and Kantarjian, H. M. The biology of chronic myeloid leukemia. N.Engl.J Med., 341: 164–172, 1999.

    Article  CAS  PubMed  Google Scholar 

  57. Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C. J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., Demetri, G. D., Fletcher, C. D., and Fletcher, J. A. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors. Science, 299: 708–710, 2003.

    Article  CAS  PubMed  Google Scholar 

  58. Carney, J. A., Sheps, S. G., Go, V. L., and Gordon, H. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N.Engl.J.Med., 296: 1517–1518, 1977.

    CAS  PubMed  Google Scholar 

  59. Carney, J. A. Gastric stromal sarcoma, pulmonary chondroma, and extraadrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin.Proc., 74: 543–552, 1999.

    CAS  PubMed  Google Scholar 

  60. Kerr, J. Z., Hicks, M. J., Nuchtern, J. G., Saldivar, V., Heim-Hall, J., Shah, S., Kelly, D. R., Cain, W. S., and Chintagumpala, M. M. Gastrointestinal autonomic nerve tumors in the pediatric population: a report of four cases and a review of the literature. Cancer, 85: 220–230, 1999.

    Article  CAS  PubMed  Google Scholar 

  61. Li, P., Wei, J., West, A. B., Perle, M., Greco, M. A., and Yang, G. C. Epithelioid gastrointestinal stromal tumor of the stomach with liver metastases in a 12-year-old girl: aspiration cytology and molecular study. Pediatr.Dev.Pathol., 5: 386–394, 2002.

    Article  PubMed  Google Scholar 

  62. Hamanaka, S., Hamanaka, Y., Yamashita, Y., and Otsuka, F. Leiomyoblastoma and leiomyomatosis of the small intestine in a case of von Recklinghausen’s disease. J.Dermatol., 24: 117–119, 1997.

    CAS  PubMed  Google Scholar 

  63. Ishida, T., Wada, I., Horiuchi, H., Oka, T., and Machinami, R. Multiple small intestinal stromal tumors with skeinoid fibers in association with neurofibromatosis 1 (von Recklinghausen’s disease). Pathol.Int., 46: 689–695, 1996.

    CAS  PubMed  Google Scholar 

  64. Min, K. W. and Balaton, A. J. Small intestinal stromal tumors with skeinoid fibers in neurofibromatosis: report of four cases with ultrastructural study of skeinoid fibers from paraffin blocks. Ultrastruct.Pathol., 17: 307–314, 1993.

    CAS  PubMed  Google Scholar 

  65. Schaldenbrand, J. D. and Appelman, H. D. Solitary solid stromal gastrointestinal tumors in von Recklinghausen’s disease with minimal smooth muscle differentiation. Hum Pathol, 15: 229–232, 1984.

    CAS  PubMed  Google Scholar 

  66. Walsh, N. M. and Bodurtha, A. Auerbach’s myenteric plexus. A possible site of origin for gastrointestinal stromal tumors in von Recklinghausen’s neurofibromatosis. Arch.Pathol.Lab Med., 114: 522–525, 1990.

    CAS  PubMed  Google Scholar 

  67. Boldorini, R., Tosoni, A., Leutner, M., Ribaldone, R., Surico, N., Comello, E., and Min, K. W. Multiple small intestinal stromal tumours in a patient with previously unrecognised neurofibromatosis type 1: immunohistochemical and ultrastructural evaluation. Pathology, 33: 390–395, 2001.

    Article  CAS  PubMed  Google Scholar 

  68. Zoller, M. E., Rembeck, B., Oden, A., Samuelsson, M., and Angervall, L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer, 79: 2125–2131, 1997.

    CAS  PubMed  Google Scholar 

  69. Blanke, C. D., Eisenberg, B. L., and Heinrich, M. C. Gastrointestinal stromal tumors. Current Treatment Options in Oncology, 2: 485–491, 2001.

    CAS  PubMed  Google Scholar 

  70. Ng, E. H., Pollock, R. E., and Romsdahl, M. M. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer, 69: 1334–1341, 1992.

    CAS  PubMed  Google Scholar 

  71. van Glabbeke, M., Hogendoorn, P. C., Mouridsen, H., Radford, J. A., Verweij, J., Rodenhuis, S., le Cesne, A., Buesa, J., Keizer, H. J., Van Oosterom, A., and Nielsen, O. Progression free fate as the principal end-point for phase II trial on soft tissue sarcoma: what should be the target? Proc Am Soc Clin Oncol 20, 345a. 2001.

    Google Scholar 

  72. Edmonson, J., Marks, R., Buckner, J., and Mahoney, M. Contrast of response to D-MAP + Sargramostim between patients with advance malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Proc Am Soc Clin Oncol 18, 541a. 1999.

    Google Scholar 

  73. Tuveson, D. A., Willis, N. A., Jacks, T., Griffin, J. D., Singer, S., Fletcher, C. D., Fletcher, J. A., and Demetri, G. D. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene, 20: 5054–5058, 2001.

    Article  CAS  PubMed  Google Scholar 

  74. Heinrich, M. C., Griffith, D. J., Druker, B. J., Wait, C. L., Ott, K. A., and Zigler, A. J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood, 96: 925–932, 2000.

    CAS  PubMed  Google Scholar 

  75. Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C., Tervahartiala, P., Tuveson, D., Silberman, S. L., Capdeville, R., Dimitrijevic, S., Druker, B. J., and Demetri, G. D. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med, 1052: 1052–1056, 2001.

    Google Scholar 

  76. Van Oosterom, A. T., Judson, I., Verweij, J., Di Paola, E., Dimitrijevic, S., Dumez, H., Scurr, M., Sciot, R., Silberman, S., van Glabbeke, M., and Nielsen, O. S. Update of the Imatinib (STI571, Glivec) phase I study in gastro intestinal stromal tumours (GISTs). Proc Am Soc Clin Oncol 21, 82a. 2002.

    Google Scholar 

  77. Van Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., Donato, d. P., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., van Glabbeke, M., Silberman, S., and Nielsen, O. S. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet, 358: 1421–1423, 2001.

    PubMed  Google Scholar 

  78. Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., Fletcher, J. A., Silverman, S. G., Silberman, S. L., Capdeville, R., Kiese, B., Peng, B., Dimitrijevic, S., Druker, B. J., Corless, C., Fletcher, C. D., and Joensuu, H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J Med., 347: 472–480, 2002.

    Article  CAS  PubMed  Google Scholar 

  79. von Mehren, M., Blanke, C. D., Joensuu, H., Heinrich, M. C., Roberts, P. J., Eisenberg, B. L., Silberman, S., Dimitrijevic, S., Kiese, B., Fletcher, Jonathan A., Fletcher, Christopher D. M., and Demetri, G. D. High incidence of durable responses induced by imatinib mesylate (Gleevec) in patients with unresectable and metastatic gastrointestinal stromal tumors (GISTs). Proc Am Soc Clin Oncol 21, 403a. 2002.

    Google Scholar 

  80. Fletcher, C. D. and Fletcher, J. A. Testing for KIT (CD117) in gastrointestinal stromal tumors: another HercepTest? Am J Clin. Pathol, 118: 163–164, 2002.

    Article  PubMed  Google Scholar 

  81. Hornick, J. L. and Fletcher, C. D. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin. Pathol, 117: 188–193, 2002.

    PubMed  Google Scholar 

  82. Mace, J., Sybil, B. J., Sondak, V., McGinn, C., Hayes, C., Thomas, D., and Baker, L. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer, 95: 2373–2379, 2002.

    Article  CAS  PubMed  Google Scholar 

  83. Miettinen, M., Sobin, L. H., and Sarlomo-Rikala, M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod. Pathol., 13: 1134–1142, 2000.

    CAS  PubMed  Google Scholar 

  84. Miettinen, M. Are desmoid tumors KIT positive? Am. J. Surg. Pathol., 25: 549–550, 2001.

    CAS  PubMed  Google Scholar 

  85. Montgomery, E., Torbenson, M. S., Kaushal, M., Fisher, C., and Abraham, S. C. Beta-catenin immunohistochemistry separates mesenteric fibromatosis from gastrointestinal stromal tumor and sclerosing mesenteritis. Am. J. Surg. Pathol., 26: 1296–1301, 2002.

    Article  PubMed  Google Scholar 

  86. Sarlomo-Rikala, M., Kovatich, A. J., Barusevicius, A., and Miettinen, M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod. Pathol., 11: 728–734, 1998.

    CAS  PubMed  Google Scholar 

  87. Sabah, M., Leader, M., and Kay, E. The Problem With KIT: Clinical Implications and Practical Difficulties With CD117 Immunostaining. Appl. Immunohistochem. Mol. Morphol., 11: 56–61, 2003.

    Article  CAS  PubMed  Google Scholar 

  88. Bauer, S., Corless, C. L., Heinrich, M. O., Dirsch, O., Antoch, G., Kanja, J., Seeber, S., and Schutte, J. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother. Pharmacol., 51: 261–265, 2003.

    PubMed  Google Scholar 

  89. Van den Abbeele, A. D., Badawi, R. D., Cliche, J., Janicek, M. J., Tetrault, R., Spangler, T., Potter, A., Merriam, P., Silberman, S., Dimitrijevic, S., and Demetri, G. 18F-FDG-PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol 21, 403a. 2002.

    Google Scholar 

  90. O’Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., Lechner, K., Nielsen, J. L., Rousselot, P., Reiffers, J., Saglio, G., Shepherd, J., Simonsson, B., Gratwohl, A., Goldman, J. M., Kantarjian, H., Taylor, K., Verhoef, G., Bolton, A. E., Capdeville, R., and Druker, B. J. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J Med., 348: 994–1004, 2003.

    Google Scholar 

  91. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. L. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 344: 1031–1037, 2001.

    CAS  PubMed  Google Scholar 

  92. Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., and Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl. J Med., 344: 1038–1042, 2001.

    CAS  PubMed  Google Scholar 

  93. Apperley, J. F., Gardembas, M., Melo, J. V., Russell-Jones, R., Bain, B. J., Baxter, E. J., Chase, A., Chessells, J. M., Colombat, M., Dearden, C. E., Dimitrijevic, S., Mahon, F. X., Marin, D., Nikolova, Z., Olavarria, E., Silberman, S., Schultheis, B., Cross, N. C. P., and Goldman, J. M. Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta. The New England Journal of Medicine, 347: 481–487, 2002.

    Article  CAS  PubMed  Google Scholar 

  94. Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., Cross, N. C., Tefferi, A., Malone, J., Alam, R., Schrier, S. L., Schmid, J., Rose, M., Vandenberghe, P., Verhoef, G., Boogaerts, M., Wlodarska, I., Kantarjian, H., Marynen, P., Coutre, S. E., Stone, R., and Gilliland, D. G. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med., 348: 1201–1214, 2003.

    Article  CAS  PubMed  Google Scholar 

  95. McArthur, G, Demetri, G., Heinrich, M., Van Oosterom, A., Fletcher, C., Corless, C., Fletcher, J. A., Dimitrijevic, S., and Nikolova, Z. Molecular and clinical analysis of response to imatinib for locally advanced dermato fibrosarcoma protuberans. Proceedings of ASCO 2003, 195. 2003.

    Google Scholar 

  96. Maki, R. G., Awan, R. A., Dixon, R. H., Jhanwar, S., and Antonescu, C. R. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int. J Cancer, 100: 623–626, 2002.

    Article  CAS  PubMed  Google Scholar 

  97. Rubin, B. P., Schuetze, S. M., Eary, J. F., Norwood, T. H., Mirza, S., Conrad, E. U., and Bruckner, J. D. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin. Oncol., 20: 3586–3591, 2002.

    Article  CAS  PubMed  Google Scholar 

  98. Sandberg, A. A. Cytogenetics and molecular genetics of bone and soft-tissue tumors. Am J Med. Genet, 115: 189–193, 2002.

    PubMed  Google Scholar 

  99. Mackall, C. L., Meltzer, P. S., and Helman, L. J. Focus on sarcomas. Cancer Cell, 2: 175–178, 2002.

    Article  CAS  PubMed  Google Scholar 

  100. Bennicelli, J. L. and Barr, F. G. Chromosomal translocations and sarcomas. Curr. Opin. Oncol, 14: 412–419, 2002.

    Article  CAS  PubMed  Google Scholar 

  101. Deguchi, K. and Gilliland, D. G. Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML. Leukemia, 16: 740–744, 2002.

    Article  CAS  PubMed  Google Scholar 

  102. Kelly, L. M. and Gilliland, D. G. Genetics of Myeloid Leukemias. Annu Rev Genomics Hum Genet, 3: 179–198, 2002.

    Article  CAS  PubMed  Google Scholar 

  103. Dash, A. B., Williams, I. R., Kutok, J. L., Tomasson, M. H., Anastasiadou, E., Lindahl, K., Li, S., Van Etten, R. A., Borrow, J., Housman, D., Druker, B., and Gilliland, D. G. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc. Natl. Acad. Sci. U. S. A, 99: 7622–7627, 2002.

    Article  CAS  PubMed  Google Scholar 

  104. Kelly, L. M., Kutok, J. L., Williams, I. R., Boulton, C. L., Amaral, S. M., Curley, D. P., Ley, T. J., and Gilliland, D. G. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl. Acad. Sci. U. S. A, 99: 8283–8288, 2002.

    CAS  PubMed  Google Scholar 

  105. Fenaux, P., Chastang, C., Chevret, S., Sanz, M., Dombret, H., Archimbaud, E., Fey, M., Rayon, C., Huguet, F., Sotto, J. J., Gardin, C., Makhoul, P. C., Travade, P., Solary, E., Fegueux, N., Bordessoule, D., Miguel, J. S., Link, H., Desablens, B., Stamatoullas, A., Deconinck, E., Maloisel, F., Castaigne, S., Preudhomme, C., and Degos, L. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood, 94: 1192–1200, 1999.

    CAS  PubMed  Google Scholar 

  106. Sohal, J., Phan, V. T., Chan, P. V., Davis, E. M., Patel, B., Kelly, L. M., Abrams, T. J., O’Farrell, A. M., Gilliland, D. G., Le Beau, M. M., and Kogan, S. C. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood, 101: 3188–3197, 2003.

    Article  CAS  PubMed  Google Scholar 

  107. Nielsen, T. O., West, R. B., Linn, S. C., Alter, O., Knowling, M. A., O’Connell, J. X., Zhu, S., Fero, M., Sherlock, G., Pollack, J. R., Brown, P. O., Botstein, D., and Van de Rijn, M. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet, 359: 1301–1307, 2002.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine and Pathology, Oregon Health Science University Cancer Institute and Portland VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, OR, 97201, USA

    Michael C. Heinrich MD & Christopher L. Corless

Authors
  1. Michael C. Heinrich MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher L. Corless
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands

    Jaap Verweij

  2. Department of Medical Oncology, Free University Medical Center, Amsterdam, The Netherlands

    Herbert M. Pinedo

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Kluwer Academic Publishers

About this chapter

Cite this chapter

Heinrich, M.C., Corless, C.L. (2004). Targeting mutant kinases in Gastrointestinal Stromal Tumors: A paradigm for molecular therapy of other sarcomas. In: Verweij, J., Pinedo, H.M. (eds) Targeting Treatment of Soft Tissue Sarcomas. Cancer Treatment and Research, vol 120. Springer, Boston, MA. https://doi.org/10.1007/1-4020-7856-0_8

Download citation

  • DOI: https://doi.org/10.1007/1-4020-7856-0_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4020-7808-8

  • Online ISBN: 978-1-4020-7856-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation